Hiroya Iida1, Masaki Kaibori2, Fumitoshi Hirokawa3, Yoshihiro Inoue3, Masaki Ueno4, Kousuke Matsui2, Morihiko Ishizaki2, Shogo Tanaka5, Shigekazu Takemura5, Takeo Nomi6, Daisuke Hokutou6, Takehiro Noda7, Hidetoshi Eguchi7, Takuya Nakai8, Hiromitsu Maehira1, Haruki Mori1, Masaji Tani1, Shoji Kubo5. 1. Department of Surgery, Shiga University of Medical Science, Otsu, Japan. 2. Department of Surgery, Kansai Medical University, Hirakata, Japan. 3. Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan. 4. Second Department of Surgery, Wakayama Medical University, Wakayama, Japan. 5. Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. 6. Department of Surgery, Nara Medical University, Kashihara, Japan. 7. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. 8. Department of Surgery, Faculty of Medicine, Kinki University, Osaka-sasayama, Japan.
Abstract
BACKGROUND: Hepatic resection (HR) is not recommended for intermediate-stage hepatocellular carcinoma (HCC) by the Barcelona Clinic Liver Cancer criteria. We examined the prognostic factors of HR for intermediate-stage HCC and developed new HR criteria for intermediate-stage HCC. METHODS: A total of 110 patients who underwent HR without any prior treatment for intermediate-stage HCC between January 2007 and December 2012 were enrolled at eight university hospitals. The outcomes and prognostic factors of HR were evaluated to develop new HR criteria. RESULTS: In terms of tumor size and number, the most significant prognostic factors were within the up-to-seven criteria. Furthermore, serum albumin level ≥35 g/L and serum alpha-fetoprotein (AFP) level.
BACKGROUND: Hepatic resection (HR) is not recommended for intermediate-stage hepatocellular carcinoma (HCC) by the Barcelona Clinic Liver Cancer criteria. We examined the prognostic factors of HR for intermediate-stage HCC and developed new HR criteria for intermediate-stage HCC. METHODS: A total of 110 patients who underwent HR without any prior treatment for intermediate-stage HCC between January 2007 and December 2012 were enrolled at eight university hospitals. The outcomes and prognostic factors of HR were evaluated to develop new HR criteria. RESULTS: In terms of tumor size and number, the most significant prognostic factors were within the up-to-seven criteria. Furthermore, serum albumin level ≥35 g/L and serum alpha-fetoprotein (AFP) level.
Authors: Delia D'Avola; Mercedes Iñarrairaegui; Fernando Pardo; Fernando Rotellar; Pablo Marti; José I Bilbao; Antonio Martinez-Cuesta; Alberto Benito; Felix Alegre; Erica Mauleón; José I Herrero; Jorge Quiroga; Jesus Prieto; Bruno Sangro Journal: Ann Surg Oncol Date: 2011-01-26 Impact factor: 5.344
Authors: R Ciria; P López-Cillero; A-B Gallardo; J Cabrera; M Pleguezuelo; M-D Ayllón; A Luque; L Zurera; J-J Espejo; M Rodríguez-Perálvarez; J-L Montero; M de la Mata; J Briceño Journal: Eur J Surg Oncol Date: 2015-06-12 Impact factor: 4.424
Authors: Myung Han Hyun; Young-Sun Lee; Ji Hoon Kim; Chan Uk Lee; Young Kul Jung; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Kwan Soo Byun Journal: Hepatology Date: 2018-05-21 Impact factor: 17.425
Authors: Richard Bell; Sanjay Pandanaboyana; J Peter A Lodge; K Raj Prasad; Rebecca Jones; Ernest Hidalgo Journal: Langenbecks Arch Surg Date: 2016-07-25 Impact factor: 3.445